Treatment of multiple sclerosis

Results: 202



#Item
31MSSocietyWA_32ppA4_TheBulletin_Autumn14_V8.indd

MSSocietyWA_32ppA4_TheBulletin_Autumn14_V8.indd

Add to Reading List

Source URL: d1qmnn0xkv8u83.cloudfront.net

Language: English - Date: 2014-04-11 01:45:07
32

PDF Document

Add to Reading List

Source URL: www.msif.org

Language: English - Date: 2014-10-14 05:07:05
33Microsoft Word - Sanofi- 5.1 alemtuzumabPSD final.docx

Microsoft Word - Sanofi- 5.1 alemtuzumabPSD final.docx

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-04-22 23:39:46
34Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI PROTECT WP5 IMI Report 2:b:iv NATALIZUMAB WAVE 2 CASE STUDY REPORT Review of methodologies for benefit and

Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI PROTECT WP5 IMI Report 2:b:iv NATALIZUMAB WAVE 2 CASE STUDY REPORT Review of methodologies for benefit and

Add to Reading List

Source URL: protectbenefitrisk.eu

Language: English - Date: 2014-07-16 01:09:14
35Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI WP5 Report 1:b:iv Benefit-Risk Wave 1 case study report: NATALIZUMAB Risk benefit case study with a focus on testing methodology.

Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI WP5 Report 1:b:iv Benefit-Risk Wave 1 case study report: NATALIZUMAB Risk benefit case study with a focus on testing methodology.

Add to Reading List

Source URL: protectbenefitrisk.eu

Language: English - Date: 2014-07-16 01:09:12
36Post-market Review of Authority Required PBS Listings: Public Consultation Submission from Biogen Idec (Australia) Pty Ltd regarding disease-modifying therapies for Multiple Sclerosis (first tranche of reviews) Dear PBAC

Post-market Review of Authority Required PBS Listings: Public Consultation Submission from Biogen Idec (Australia) Pty Ltd regarding disease-modifying therapies for Multiple Sclerosis (first tranche of reviews) Dear PBAC

Add to Reading List

Source URL: pbs.gov.au

Language: English - Date: 2015-03-02 18:33:43
37Physical Actitivty in the Prevention of Treatment and Desease

Physical Actitivty in the Prevention of Treatment and Desease

Add to Reading List

Source URL: fyss.se

Language: English - Date: 2011-06-20 11:53:02
38Treatments for MS: TECFIDERA® (dimethyl fumarate) There are currently nine disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity i

Treatments for MS: TECFIDERA® (dimethyl fumarate) There are currently nine disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity i

Add to Reading List

Source URL: www.msaustralia.org.au

Language: English - Date: 2014-01-21 00:35:16
39Living Well with MS Fact Sheet What is Multiple Sclerosis? Multiple sclerosis (MS) is a disease of the central nervous system (CNS) affecting the brain, spinal cord and optic nerves. The CNS acts as the body’s messeng

Living Well with MS Fact Sheet What is Multiple Sclerosis? Multiple sclerosis (MS) is a disease of the central nervous system (CNS) affecting the brain, spinal cord and optic nerves. The CNS acts as the body’s messeng

Add to Reading List

Source URL: d1qmnn0xkv8u83.cloudfront.net

Language: English - Date: 2013-10-22 04:45:48
40February 5, 2014 New treatment gives hope to MS patients The Multiple Sclerosis Society of WA (MSWA) CEO Marcus Stafford says the breakthrough in the treatment of progressive multiple sclerosis (MS) by Australian resear

February 5, 2014 New treatment gives hope to MS patients The Multiple Sclerosis Society of WA (MSWA) CEO Marcus Stafford says the breakthrough in the treatment of progressive multiple sclerosis (MS) by Australian resear

Add to Reading List

Source URL: d1qmnn0xkv8u83.cloudfront.net

Language: English - Date: 2014-02-24 22:00:06